Samsara Vision

Samsara Vision has developed implantable ophthalmic devices and technologies intended to significantly improve vision and quality of life for individuals with end-stage age-related macular degeneration. The company's lead product, the Implantable Miniature Telescope, is integral to the CentraSight treatment program, which has been developed to help patients follow the necessary steps for proper diagnosis, surgical evaluation, and postoperative care. The Implantable Telescope technology platform is based on wide-angle micro-optics that in combination with the optics of the cornea, create a telephoto system that magnifies objects in view. The telescope implant is surgically placed in the capsular bag after removal of the eye's lens. Implantation inside the eye allows the patient to see using natural eye movements in both stationary and dynamic environments. The Implantable Miniature Telescope has received FDA approval. Samsara Vision also holds a CE mark and has received approval from the Israel Ministry of Health for distribution and sale of the device.

Samsara Vision has raised $90.5M in total funding across 6 rounds. The company is currently at the Mature stage. Key investors include Undisclosed Investor(s), BSI SA, Pitango VC.

Samsara Vision operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics, with core technologies in Materials & Substances, Implants. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Insurance Companies.

Samsara Vision is based in Yegi'a Kapayim Street 21, Petah Tikva, Israel, Center District. The company also has offices abroad.